Company intelligence / Profile preview

Kuzani Pharmaceuticals

Unknown/not publicly disclosed, Unknown/not publicly disclosed, United Statescrunchbase.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Kuzani Pharmaceuticals is developing novel medicines for neurodevelopmental disorders, most notably working on repurposing and developing suramin for the treatment of autism. The company has been collaborating with Dr. Robert Naviaux and was scheduled to begin a multi-center trial delayed by COVID, with hopes to start post-pandemic. Clinical results have not been widely published as of early 2025

Therapeutic areas: Neurology
Modalities: Small molecules (notably suramin for autism)
Industry: Biotech

Partnerships

Collaboration with Dr. Robert Naviaux at UC San Diego noted in media reports

Beyond the preview

Go deeper on Kuzani Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kuzani Pharmaceuticals.

Explore the full profile